inclusion criteria: 1. participants of 18 years of age or older, at the time of signing of informed consent. 2. have a positive sars-cov-2 test result, and sample collection for the first positive sars-cov-2 viral infection determination ≤5 days prior to the first dose. note: pcr is the preferred method; however, with evolving approaches to laboratory confirmation of sars-cov-2 infection, other molecular or antigen tests that detect viral rna or protein are allowed if authorized for use in the country. serological tests that detect host antibodies generated in response to recent or prior infection are not allowed. 3. initial onset of symptoms of covid-19 ≤3 days prior to the first dose. 4. have any of the following targeted covid-19-related symptoms with covid-19 related symptoms score ≥2 within 24 hours before the first dose: fever cough sore throat stuffy or running nose, headache muscle or body aches shortness of breath or difficulty breathing nausea chills or shivering vomiting diarrhea 5. agree to adhere to contraception restrictions.contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. 6. understand and agree to comply with planned study procedures. 7. can give written informed consent approved by the ethical review board governing the site and comply with the requirements and restrictions listed in the informed consent form (icf) and in this protocol.

inclusion criteria: 1. participants of 18 years of age or older, at the time of signing of informed consent. 2. have a positive sars-cov-2 test result, and sample collection for the first positive sars-cov-2 viral infection determination ≤5 days prior to the first dose. note: pcr is the preferred method; however, with evolving approaches to laboratory confirmation of sars-cov-2 infection, other molecular or antigen tests that detect viral rna or protein are allowed if authorized for use in the country. serological tests that detect host antibodies generated in response to recent or prior infection are not allowed. 3. initial onset of symptoms of covid-19 ≤3 days prior to the first dose. 4. have any of the following targeted covid-19-related symptoms with covid-19 related symptoms score ≥2 within 24 hours before the first dose: fever cough sore throat stuffy or running nose, headache muscle or body aches shortness of breath or difficulty breathing nausea chills or shivering vomiting diarrhea 5. agree to adhere to contraception restrictions.contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. 6. understand and agree to comply with planned study procedures. 7. can give written informed consent approved by the ethical review board governing the site and comply with the requirements and restrictions listed in the informed consent form (icf) and in this protocol.

inclusion criteria: participants of 18 years of age or older, at the time of signing of informed consent. have a positive sars-cov-2 test result, and sample collection for the first positive sars-cov-2 viral infection determination ≤5 days prior to the first dose. note: pcr is the preferred method; however, with evolving approaches to laboratory confirmation of sars-cov-2 infection, other molecular or antigen tests that detect viral rna or protein are allowed if authorized for use in the country. serological tests that detect host antibodies generated in response to recent or prior infection are not allowed. initial onset of symptoms of covid-19 ≤3 days prior to the first dose. have any of the following targeted covid-19-related symptoms with covid-19 related symptoms score ≥2 within 24 hours before the first dose: fever cough sore throat stuffy or running nose, headache muscle or body aches shortness of breath or difficulty breathing nausea chills or shivering vomiting diarrhea agree to adhere to contraception restrictions.contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. understand and agree to comply with planned study procedures. can give written informed consent approved by the ethical review board governing the site and comply with the requirements and restrictions listed in the informed consent form (icf) and in this protocol.

inclusion criteria: participants of 18 years of age or older, at the time of signing of informed consent. have a positive sars-cov-2 test result, and sample collection for the first positive sars-cov-2 viral infection determination ≤5 days prior to the first dose. note: pcr is the preferred method; however, with evolving approaches to laboratory confirmation of sars-cov-2 infection, other molecular or antigen tests that detect viral rna or protein are allowed if authorized for use in the country. serological tests that detect host antibodies generated in response to recent or prior infection are not allowed. initial onset of symptoms of covid-19 ≤3 days prior to the first dose. have any of the following targeted covid-19-related symptoms with covid-19 related symptoms score ≥2 within 24 hours before the first dose: fever cough sore throat stuffy or running nose, headache muscle or body aches shortness of breath or difficulty breathing nausea chills or shivering vomiting diarrhea agree to adhere to contraception restrictions.contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. understand and agree to comply with planned study procedures. can give written informed consent approved by the ethical review board governing the site and comply with the requirements and restrictions listed in the informed consent form (icf) and in this protocol.